C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
Operating Income
C4 Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Operating Income
-$117.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
C4 Therapeutics Inc
Glance View
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
See Also
What is C4 Therapeutics Inc's Operating Income?
Operating Income
-117.2m
USD
Based on the financial report for Dec 31, 2024, C4 Therapeutics Inc's Operating Income amounts to -117.2m USD.
What is C4 Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-27%
Over the last year, the Operating Income growth was 16%. The average annual Operating Income growth rates for C4 Therapeutics Inc have been -13% over the past three years , -27% over the past five years .
You don't have any saved screeners yet